Hormonal factors in aetiology and therapy of acne vulgaris;Rola czynników hormonalnych w etiopatogenezie i terapii tradziku pospolitego

Postepy Dermatologii i Alergologii

Volumn 23, Issue 6, 2006, Pages 266-272

  Sobjanek, Michał ^a   Sokołowska Wojdyło, Małgorzata ^a   Barańska Rybak, Wioletta ^a   Nowicki, Roman ^a   Włodarkiewicz, Adam ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Acne vulgaris; Androgens; Oral contraceptives

Indexed keywords

ADAPALENE; AKNOTEN; ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; ANTIBIOTIC AGENT; ATREDERM; CONTRACEPTIVE AGENT; CORTICOTROPIN; CYPROTERONE; FINASTERIDE; FLUTAMIDE; GROWTH HORMONE; INTERLEUKIN 10; INTERMEDIN; ISOTRETINOIN; MELANOCORTIN; MELANOCORTIN RECEPTOR; MINOCYCLINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PRASTERONE; RETINOIC ACID; RETINOIC ACID BINDING PROTEIN; RETINOIC ACID RECEPTOR; RETINOID X RECEPTOR; SEX HORMONE; SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN C; SPIRONOLACTONE; TAZAROTENE; TESTOSTERONE 17BETA DEHYDROGENASE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACNE VULGARIS; DOCTOR PATIENT RELATION; DRUG USE; HUMAN; PATHOGENESIS; REVIEW; RISK FACTOR; SEBACEOUS GLAND;

EID: 33846622892     PISSN: 1642395X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Błaszczyk-Kostanecka M, Chodynicka B, Gliński W i wsp. Tradzik pospolity: patogeneza i zasady leczenia. Przegl Dermatol 1998; 85: 3-19.
2. Stathakis V, Kilkenny M, Marks R. Descriptive epidemiology of acne vulgaris in the community. Austral J Dermatol 1997; 38: 115-23.
3. Braun-Falco O, Plewig G, Wolf HH, et al. Dermatologia. Gliński W, Wolska H (red.). Czelej, Lublin 2004; 993-1007.
4. Johnson BA, Nunley JR. Topical therapy for acne vulgaris: how do you choose the best drug for each patient? Postgrad Med 2000; 107: 69-80.
5. Gibson JR. Rationale for the development of new topical treatments for acne vulgaris. Cutis 1996; 57 (suppl. 1): 13-9.
6. Gollick H, Schramm M. Topical drug treatment in acne. Dermatology 1998; 196: 119-25.
7. Healy E, Simpson N. Acne vulgaris. BMJ 1994; 308: 831-3.
8. Deplewski D, Rosenfield RL Role of hormones in pilosebaceous unit development. Endocr Rev 2000; 21: 363-92.
9. Cunliffe WJ. A new topical retinoid-why a new topical acne therapy? Br J Dermatol 1998; 139 (suppl. 52): 1-2.
10. Cunliffe WJ, Caputo R, Dreno B, et al. Clinical efficacy and safety comparison of adapalene gel and tretinoin gel in the treatment of acne vulgaris: Europe and US multicenter trials. J Am Acad Dermatol 1997; 36: S126-34.
11. Kakita L Tazarotene versus tretinoin or adapalene in the treatment of acne vulgaris. J Am Acad Dermatol 2000; 8: 51-4.
12. Lucky AW, Cullen SI, Funicella T, et al. Double-blind, vehicle-controlled, multicenter comparison of two 0.025% tretinoin creams in patients with acne vulgaris. J Am Acad Dermatol 1998; (suppl. 38): 24-30.
13. Cunliffe WJ. Acne, hormones, and treatment. Br Med J 1982; 285: 912-3.
14. Strauss JS, Kligman AM, Pochi PE. The effect of androgens and estrogens on human sebaceous glands. J Invest Dermatol 1962; 39: 139-55.
15. Thiboutot D. Acne: hormonal concepts and therapy. Clin Dermatol 2004; 22: 419-28.
16. Labrie F, Luu-The V, Polletier G, et al. Intracrinology and the skin. Horm Res 2000; 54: 213-29.
17. Thiboutot D, Knaggs HE, Gilliland K. Activity of 5-α-reductase and 17-β-hydroxysteroid dehydrogenase in the infrainfundibulum of subjects with and without acne vulgaris. Dermatology 1998; 196: 38-42.
18. Manson J. The 3β-hydroxysteroid dehydrogenase gene family of enzyms. Trend in Endocrin Metab 1993; 4: 199-202.
19. Thiboutot D, Martin P, Volikos L, et al. Oxidative activity of the type 2 isoezyme of 17β-hydroxysteroid dehydrogenase (17β-HSD) predominates in human seboceous glands. J Inves Dermatol 1998; 111: 390-5.
20. Mangelsdorf DJ, Thummel C, Beato M, et al. The nuclear receptors superfamily: the second decade. Cell 1995; 83: 835-9.
21. Akamatsu H, Zouboulis C, Orfanos CE. Control of human sebocyte proliferation in vitro by testosterone and 5α-dihydrotestosterone is dependent on the localizaton of the sebaceous glands. J Invest Dermatol 1992; 99: 509-11.
22. Rosenfield RL, Deplewski D, Greene ME. Peroxisome proliferator-activated receptors and skin development. Horm Res 2000; 54: 269-74.
23. Schonjans K, Staels B, Auwerx J. The peroxisome proliferator activated receptors (PPARs) and their effects in lipid metabolism and adipocyte differentiation. Biochim Biophys Acta 1996; 1302: 93-109.
24. Darley CR, Moore JW, Besser GM. Androgen status in women with late onset and persistent acne vulgaris. Clin Exp Dermatol 1984; 9: 28-35.
25. Pochi PE, Comite H, Longcope C. Adrenocortical response to exogenous ACTH in woman with chronic, treatment resistant acne.
26. Cibula D, Hill M, Vohradnikova O. The role of androgens in determining acne severity in adult women. Br J Dermatol 2000; 143: 399-404.
27. Marynick SP, Chakmakjian ZH, McCaffreeDL, et al. Androgen excess in cystic acne. N Engl J Med 1983; 308: 981-6.
28. Chrousos GP, Peck GL, Gross EG, et al. Adrenal function in women with idiopathic acne. J Invest Dermatol 1982; 78: 468-71.
29. Haroun M. Hormonal therapy of acne. J Cutan Med Surg 2004; 8 (Suppl 4): 6-10.
30. Sawaya ME, Price VH. Differentlevels of 5α-reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenic alopecia. J Invest Dermatol 1997; 109: 296-300.
31. Deplewski D, Rosenfield RL Growth hormone and insuline-like growth factors have different effects on sebaceous cell growth and differentiation. Endo 1999; 140: 4089-94.
32. Bohm M, Luger TA. The pilosebaceous unit is a part of skin immune system. Dermatology 1998; 196: 75-9.
33. Bohm M, Schiller M, Stander S, et al. Evidence for expresion of melanocortin-1receptor in human sebocytes in vitro and in situ. J Invest Dermatol 2002; 188: 533-9.
34. Thody AJ, Shuster S. Control of sebaceous gland function in the rat by alpha-melanocyte-stimulaling hormone. J Endocrinol 1975; 64: 503-10.
35. Zhang L, Wen-Hwa L, Anthonavage M, et al. Melanocortin-5 receptor: A marker of human sebocyte differentiation. Peptides 2006; 27: 413-20.
36. Chen W, Kelly MA, Opitz-Araya X, et al. Exocrine gland dysfunction in MC5R-deficent mice:evidence for coordinated regulation of exocrine gland function by melanocortin peptides. Cell 1997; 91: 789-98.
37. Plewig G. Treatment modalities of acne. Derm Klin Zabieg 2001; 3: 122.
38. Zouboulis CC, Korage B, Akamatsu H, et al. Effects of 13-cis retinoic acid, all-trans-retinoic acid, and acitrecin on the proliferation, lipid synthesis and keratin expresion of cultured human sebocytes in vitro. J Invest Dermatol 1991; 96: 792-7.
39. Knochenhauer ES, Key TJ, Kashar-Miller M, et al. Prevalence of the polycystic ovary syndrome in unselected black and white woman of southeastern United States: apropective study. J Clin Endocrinol Metab 1998; 83: 3078-82.
40. Azziz R, Sanchez AL, Knochenhauer ES, et al. Androgen exess in women: experience with over 1000 consecutive patients. J Clin Endocrinol Metab 2004; 89: 453-62.
41. Shaw JC. Anti-androgen and hormonal treatment of acne. Dermatol Clin 1996; 14: 803-11.
42. Gruber DM, Sator MO, Joura EA, et al. Topical cyproterone acetate treatment in women with acne: a placebo controlled trial. Arch Dermatol 1998; 11: 210-6.
43. Shaw JC. Low-dose adjuctive spironolactone in the treatment of acne in women: aretrospective analysis of 85 consecutively treated patients. J Am Acad Dermatol 2000; 43: 498-502.
44. Lubbos HG, Hasinski S, Rose LI, et al. Adverse effects of spironolactone therapy in women with acne. Arch Dermatol 1998; 134: 1162-2.
45. Yemisci A, Gorgulu A, Piskin S. Effects and side-effects of spironolactone therapy in women with acne. J Eur Acad Dermatol Venereol 2005; 19: 163-6.
46. Shaw JC. Spironolactone in dermatologic therapy. J Am Acad Dermatol 1991; 24: 236-43.
47. Venturoli S, Paradisi R, Bangnoli A, et al. Low-dose flutamide (125 mg/ day) as maintenance therapy in the treatment of hirsutyzm. Horm Res 2001; 56: 25-31.
48. Wang HS, Wang TH, Soong YK. Low dose flutamide in the treatment of acne vulgaris in women with or witout oligomenorhea or amenorrhea. Changgeng Yi Xue Za Zhi. 1999; 223: 423-32.
49. Leyden J, Bergfeld W, Drake L, et al. A systemic type I 5α-reductase inhibitor is ineffective in the treatment of acne vulgaris. J Am Acad Dermatol 2004; 50: 443-7.
50. Greenwood R, Brummitt L, Bruke B, et al. Acne double-blind clinical and laboratory trial of tetracycline, oestrogen-cyproterone acetate, and combined treatment. Br Med J 1985; 291: 1231-5.
51. van Vloten W, van Haselen C, van Zuuren, et al. The effect of 2 combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis 2002; 69 (suppl. 4): 2-15.
52. Lemay A, Dewailly SD, Grenier R, et al. Attenuation of mild hyperandrogenic activity in postpubertal acne by a triphasic oral contraceptive containing low doses of ethynyl estradiol and D,l-norgestrel. J Clin Endocrinol Metab 1990; 71: 8-14.
53. Lucky A, Henderson T, Olson W, et al. Effectiveness of norgestimate and ethil estradiol in treating moderate acne vulgaris. J Am Acad Dermatol 1997; 37: 746-54.
54. Redmond GP, Olson WH, Lippman JS, et al. Norgestimate an etihnyl estradiol in treatment of acne vulgaris: a randomized, placebo-controlled trial. Obstet Gynecol 1997; 89: 615-22.
55. Maloney M, Arbit D, Flack M, et al. Use of s low-dose oral contraceptives containning norethidrone acetate and ethinyl estradiol in the treatment of moderate acne vulgaris. Clin J Womens Health 2001; 1: 124-31.
56. Rosing J, Tans G, Nicolaes GA, et al. Oral contraceptives and venous thromboembolism different sensitivities to activated protein C in women usin second and third generation oral contraceptives. Br J Haematol 1997; 97: 233-8.
57. Hemminiki E. Oral contraceptives and breast cancer. Br Med J 1996; 313: 63-4.
58. Baird DT, Glasier AF. Editorial: hormonal contraception. N Engl J Med 1993; 328: 1543-9.
59. Tan J. Hormonal treatment of acne: review of current best evidence. J Cutan Med Surg 2004; 8 (suppl. 4): 11-5.